Research statistics

B7-33 research: publications and trials

What has been published on B7-33: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether B7-33 works or is safe. For what it is and what the studies found, see the B7-33 profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

12

Since 2016

Publications in 2026 so far

0

Through November 15, 2026

Human clinical research

0.0%

0 of 12 classified

Registered clinical trials

0

ClinicalTrials.gov

Randomized controlled trials

0

Publications reporting an RCT in people

Systematic reviews and meta-analyses

0

Preclinical studies

91.7%

8 animal · 3 in vitro · 0 computational

Records that only mention it

2

Not counted above

Status in the library: Research only. Groups: Tissue-repair peptides.

What to keep in mind

  • No human clinical publication is indexed: everything published so far is preclinical, a review or commentary.
  • Fewer than three randomized controlled trials are indexed.
  • More than 70% of the indexed publications are animal, cell or computational studies.
  • Fewer than 25 publications are indexed, so year-to-year changes are not meaningful.

Publications by year

B7-33 publications by year and evidence

2016, Preclinical (animal, in vitro, computational): 1 of 12017, Preclinical (animal, in vitro, computational): 1 of 12019, Preclinical (animal, in vitro, computational): 1 of 22019, Reviews and meta-analyses: 1 of 22020, Preclinical (animal, in vitro, computational): 1 of 12021, Preclinical (animal, in vitro, computational): 2 of 22023, Preclinical (animal, in vitro, computational): 3 of 32025, Preclinical (animal, in vitro, computational): 2 of 2Preclinical (animal, in vitro, computational)Reviews and meta-analyses01232016201920212025
Counted PubMed publications by year of first publication. A larger bar is more publications, not stronger evidence.
Show the data
YearPreclinical (animal, in vitro, computational)Reviews and meta-analysesTotal
2016101
2017101
2019112
2020101
2021202
2023303
2025202

Study types

Animal study8
In vitro study3
Review1

Research areas

From MeSH major topics. A paper can be in several areas.

Cardiovascular9
Tissue repair4
Oncology2
Endocrinology1
Gastrointestinal1
Immune system1
Neurological and mental health1
Reproductive and sexual health1

Registered clinical trials

A registration is not a result.

No registered trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

No human trial, systematic review or meta-analysis of B7-33 is indexed.

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1.

    Chemical science · February 26, 2016 · In vitro study · cited 88 times · open access

    PMID 30155023 · DOI 10.1039/c5sc04754d · In vitro studies

  2. B7-33 replicates the vasoprotective functions of human relaxin-2 (serelaxin).

    European journal of pharmacology · May 3, 2017 · Animal study · cited 33 times

    PMID 28478069 · DOI 10.1016/j.ejphar.2017.05.005 · Animal studies

  3. Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology · May 1, 2021 · Animal study · cited 23 times

    PMID 33908676 · DOI 10.1096/fj.202002053rrr · Animal studies

  4. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.

    Journal of the American Heart Association · April 16, 2020 · Animal study · cited 20 times · open access

    PMID 32295457 · DOI 10.1161/jaha.119.015748 · Animal studies

  5. Single chain peptide agonists of relaxin receptors.

    Molecular and cellular endocrinology · January 11, 2019 · Review · cited 16 times

    PMID 30641102 · DOI 10.1016/j.mce.2019.01.008 · Reviews and meta-analyses

Latest publications

  1. Dual-functional nanovesicles simultaneously inhibit stromal fibrosis and angiogenesis to suppress cholangiocarcinoma progression.

    Journal of nanobiotechnology · December 22, 2025 · Animal study · cited 1 times · open access

    PMID 41430305 · DOI 10.1186/s12951-025-03833-w · Animal studies

  2. Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration.

    Journal of biomedical science · December 12, 2025 · Animal study · cited 1 times · open access

    PMID 41382190 · DOI 10.1186/s12929-025-01198-8 · Animal studies

  3. Further Developments towards a Minimal Potent Derivative of Human Relaxin-2.

    International journal of molecular sciences · August 11, 2023 · In vitro study · cited 6 times · open access

    PMID 37628851 · DOI 10.3390/ijms241612670 · In vitro studies

  4. A Lipidated Single-B-Chain Derivative of Relaxin Exhibits Improved In Vitro Serum Stability without Altering Activity.

    International journal of molecular sciences · April 1, 2023 · In vitro study · cited 11 times · open access

    PMID 37047588 · DOI 10.3390/ijms24076616 · In vitro studies

  5. The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · February 6, 2023 · Animal study · cited 15 times · open access

    PMID 36753958 · DOI 10.1016/j.biopha.2023.114370 · Animal studies

  6. Analgesic effect of central relaxin receptor activation on persistent inflammatory pain in mice: behavioral and neurochemical data.

    Pain reports · June 16, 2021 · Animal study · cited 9 times · open access

    PMID 34159282 · DOI 10.1097/pr9.0000000000000937 · Animal studies

  7. Assessment of renal fibrosis and anti-fibrotic agents using a novel diagnostic and stain-free second-harmonic generation platform.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology · May 1, 2021 · Animal study · cited 23 times

    PMID 33908676 · DOI 10.1096/fj.202002053rrr · Animal studies

  8. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.

    Journal of the American Heart Association · April 16, 2020 · Animal study · cited 20 times · open access

    PMID 32295457 · DOI 10.1161/jaha.119.015748 · Animal studies

  9. Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation.

    ACS applied materials & interfaces · December 2, 2019 · Animal study · cited 13 times

    PMID 31713411 · DOI 10.1021/acsami.9b17859 · Animal studies

  10. Single chain peptide agonists of relaxin receptors.

    Molecular and cellular endocrinology · January 11, 2019 · Review · cited 16 times

    PMID 30641102 · DOI 10.1016/j.mce.2019.01.008 · Reviews and meta-analyses

Browse all 12 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: B7-33

((TITLE_ABS:"B7-33" OR CHEM:"B7-33" OR TITLE_ABS:"B 7-33" OR CHEM:"B 7-33")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). B7-33 research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/b7-33